GBS (NYSE:GBS) & Bioventus (NYSE:BVS) Head to Head Survey

Bioventus (NYSE:BVS) and GBS (NYSE:GBS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk and Volatility

Bioventus has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, GBS has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

Valuation and Earnings

This table compares Bioventus and GBS”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$567.70 million	0.97	-$156.23 million	($0.48)	-13.96
GBS	$440,000.00	40.95	-$8.31 million	($0.56)	-2.16

GBS has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than GBS, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bioventus and GBS, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	2	0	2.67
GBS	0	0	0	0	0.00

Bioventus currently has a consensus price target of $14.33, indicating a potential upside of 113.93%. Given Bioventus’ stronger consensus rating and higher probable upside, analysts clearly believe Bioventus is more favorable than GBS.

Profitability

This table compares Bioventus and GBS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
GBS	N/A	-85.64%	-54.42%

Insider and Institutional Ownership

62.9% of Bioventus shares are held by institutional investors. Comparatively, 2.8% of GBS shares are held by institutional investors. 32.9% of Bioventus shares are held by company insiders. Comparatively, 0.3% of GBS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Bioventus beats GBS on 9 of the 14 factors compared between the two stocks.

About Bioventus

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About GBS

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.